Ranbaxy completes 20 years in Russia

The company established its operations in the Russian market in 1993 with the launch of its key brand, Cifran.

India’s largest pharmaceutical company, Ranbaxy Laboratories Limited (Ranbaxy) today announced that the company has completed 20 successful years in Russia. The company established its operations in the Russian market in 1993 with the launch of its key brand, Cifran. Since then, Ranbaxy has grown to become a No. 1 player with a market share of 15.4% in the represented market segment in Russia (IMS, May 2013).  With a well-established distribution network and skilled field force, Ranbaxy today has operations in 56 regions in Russia and has built strong equity with its customers. The company has a portfolio of products covering anti-infective, cold, pain management, cardiovascular, diabetology, central nervous system, urology and dermatology segments. So far, the company has registered 51 drugs in the Russian Federation and commercialised 72 SKU’s. Ranbaxy’s leading brands in Russia includes Ketanov, Coldact, Faringosept, Cifran, Pylobact and Fenules. Last year, the company’s popular brand, Faringosept was selected as the People’s brand of choice. Another well know brand, Cifran OD was ranked by IMS as the best antibiotic launch in 2004. On the occasion, Arun Sawhney, CEO & MD, Ranbaxy said, “Ranbaxy was one of the first pharmaceutical companies from India to set up operations in Russia. We have been providing high quality, affordable generic medicines to the citizens of Russia for the last two decades, thereby supporting the Government to bring down healthcare costs. We remain committed to the Russian market and will continue to operate from the paradigm of Quality and Patients First”. Aman Khanna, Country Head of Russia, Ranbaxy, said,  “Over the years, Ranbaxy has established itself a preferred generic pharmaceutical company in Russia. In the coming years, we look at further expanding our product portfolio to include value added and innovator products from our parent company, Daiichi Sankyo. We are working closely in partnership with regional Governments in line with the Russia Pharma, 2020 Healthcare Plan,” Earlier in 2011, Ranbaxy and the Government of Yaroslavl signed a Memorandum of Understanding for cooperation in the field of healthcare and medical science, which was a major milestone. As part of the program, most clinical pharmacologists and senior medical students of Yaroslavl region have been trained in Pharmacovigilance. The Russian pharmaceutical market is estimated at around US $ 20 billion (IMS, May 2013) growing at a CAGR of around 11%. The retail/out of pocket market contributes around 66% to the total market. The Federal Government in Russia is committed towards the improvement of the pharma industry with the launch of Russian Pharma 2020 strategy under which the government is encouraging pharma players to carry out heavy local investment in infrastructure, quality improvement programmes, clinical trials hubs and training for health care professionals.